Association between ABO Blood Group and COVID-19 Pneumonia Severity: A Cross-Sectional Study from Ethiopia’s First Designated COVID-19 Treatment Center

Publication date: Sep 07, 2026

ABSTRACT Background: Coronavirus disease 2019 (COVID19), caused by severe acute respiratory syndrome coronavirus 2, spreads rapidly and can cause severe acute respiratory failure; advanced age, chronic disease, and other comorbidities increase the risk of severe infection. By early 2022, more than 477 million cases and 6.11 million deaths had been reported globally. This study assessed the association between ABO blood group and severity of COVID-19 pneumonia among patients admitted to Eka Kotebe General Hospital, Addis Ababa, Ethiopia. Methods: A hospital-based cross-sectional study was conducted using systematic random sampling; data were abstracted from patient records, and severity was modeled using ordinal logistic regression, with multicollinearity and the proportional odds assumption checked via the variance inflation factor and test of parallel lines, and model fit assessed by likelihood ratio chi-square and goodness of fit tests. Results: Of 355 patients included (100% response rate), 54.9% were male and 31.0% were older than 61 years (median age, 48 years; interquartile range, 33-65). Overall, 10.14% were asymptomatic, 24.79% had mild/moderate disease, 60.56% had severe disease, and 4.51% had critical disease. Pregnancy and presence of complications were significantly associated with severity (adjusted odds ratio, 0.15 [95% CI, 0.04-0.57] and 14.96 [95% CI, 4.14-54.01], respectively); ABO blood group showed no association with severity. Conclusion: These findings demonstrate a substantial association between COVID-19 severity and complications and pregnancy, but not ABO blood group.

PDF

Concepts Keywords
Abo
Blood
Certified
Covid
Display
Ethiopia
Found
Group
Hospital
Medrxiv
Peer
Preprint
Severe
Severity
Version

Semantics

Type Source Name
disease MESH COVID-19
disease MESH severe acute respiratory syndrome
disease MESH chronic disease
disease MESH included
disease MESH Pneumonia
drug DRUGBANK Coenzyme M
disease MESH infection
disease MESH acute respiratory distress syndrome
disease MESH injury
disease MESH arrhythmia
disease MESH septic shock
disease MESH liver dysfunction
disease MESH acute kidney injury
disease MESH cancer
disease MESH cerebrovascular disease
disease MESH chronic kidney disease
disease MESH diabetes mellitus
disease MESH obesity
disease MESH cholera
disease MESH plague
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH mumps
disease MESH smallpox
disease MESH Pseudomonas aeruginosa infection
disease MESH gonorrhea
disease MESH salmonella infections
disease MESH bleeding
drug DRUGBANK Von Willebrand Factor Human
disease MESH death
drug DRUGBANK Oxygen
disease MESH communicable disease
disease MESH dementia
disease MESH mental illness
disease MESH cardiovascular disease
disease MESH hypertension
disease MESH emergency
disease MESH cerebrovascular accident
disease MESH dyspnea
drug DRUGBANK Medical air
disease MESH Critical illness
disease MESH respiratory failure
disease MESH fever
disease MESH cough
disease MESH sore throat
disease MESH nausea
disease MESH vomiting
disease MESH asthma
pathway KEGG Asthma
disease MESH Diarrhea
drug DRUGBANK Cytidine-5′-Monophosphate
disease MESH substance use
disease MESH sepsis
disease MESH face
disease MESH Neurologic manifestation
drug DRUGBANK Creatinine
disease MESH ALP
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK Esomeprazole

Download Document

(Visited 2 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *